Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07647328 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT07647328 is a Phase 3 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 150 participants.
The verdict
NCT07647328, a Phase 3 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinue the study treatment for any reason.
Interventions
- DRUG Camizestrant
- DRUG Ribociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06-15 |
| Est. Completion | 2029-02-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07647328
The ClinicalTrials.gov registry entry for NCT07647328 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Camizestrant is the first listed.
NCT07647328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07647328 about?
NCT07647328 is a clinical study titled "A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer". The purpose of this study is to investigate the efficacy, safety, and tolerability of camizestrant in combination with ribociclib in patients with ER+ HER2- BC who have not received any other systemic treatment for advanced disease. Participants will be treated within the trial until they discontinu...
What is the current status of trial NCT07647328?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06-15. Estimated completion is 2029-02-28.
What interventions are being tested in trial NCT07647328?
The interventions under investigation include: Camizestrant (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT07647328?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.